publish updat takeaway model
impress cc growth quarter especi consid
growth tough comp expect
improv diabet de solid pain perform
magnitud diabet turnaround flu benefit ad
boost even oper margin fell shi street estim sg
leverag usual bright spot quarter compound
matter announc delay fim use robot platform
sever year set expect manag chose
commit timelin share trade ntm ep estim
slightli averag close similarli grow large-cap
peer like sell pt analyst dane leon zimmer
rate top-lin upsid make us feel better hit
full-year guidanc lower expect oper margin
combin delay robot street excit
make us think multipl unlik expand near-term keep
constant think share trade mid year
takeaway revenu line came forecast
except spine in-lin diabet drove
line notabl underli de growth mid-teen y/i
basi gross margin continu less pressur cc vs
leav us less concern increment price
pressur surprisingli sg came higher expect
wonder spend bit quarter drive sale
model revis rais revenu estim
result better visibl lower om go forward
maintain revenu estim model chang
follow page
valuat rate neutral risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
consolid revenu grow report basi nearli
constant currenc basi biggest top-lin surpris much
stronger diabet revenu benefit anima
exit restor therapi pain therapi solid quarter grow
cc basi vs declin fall better
non-crm result tavr momentum continu onyx launch go
gross margin fall short model meanwhil sg
spend come wors estim spend
sale close forecast
told combin slightli lower tax rate ep match
actualsbtig estimate varianceww cardiac rhythm hf cardiac vascular group minim spine restor therapi diabet net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
notabl chang model includ
increas constant currenc revenu growth
stronger diabet cvg sale non-crm relat pain revenu
bring estim revenu growth
lower ebit margin estim reflect
currenc headwind weaker oper margin trend seen
maintain cc revenu growth rais
estim currenc tailwind note report revenu growth
look much wors realiti revenu still one
quarter divest patient busi skew y/i
trim ebit margin estim
assess recent oper trend make us cautiou around
prospect meaning ebit margin expans model
margin expans
lower tax rate reflect chang
model ep growth assum
aggress share repurchas absenc
medtron rate neutral next twelv month price-to-earnings basi
share trade estim discount large-
cap med-tech peer group howev feel current valuat warrant
given slower growth vs group inconsist around revenu
oper margin perform btig provid price target
growth adj net btig estim compani filingsnewold chang
synergi pressur spine market soft emerg
market margin degrad expans new busi line
competit slippag product timelin chang procedur
reimburs futur devic data fda use cash/m
exhibit comp tabl large-cap peer
ntm johnsonjnjsel bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap bev/salescagr
medtron incom eproduct net y/i good gross total oper expens adj oper interest expens pre-tax incom adj net non-controlling adj net incom adjust ep share total net ex select calendar net oper ep oper net product product product oper btig estim compani report
medtron revenu ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
